Yiwen Shen - Search Results

Year	Number of Results
2002	1
2003	2
2004	1
2005	1
2006	1
2007	3
2008	2
2009	1
2010	2
2011	4
2012	6
2013	6
2014	10
2015	9
2016	12
2017	7
2018	6
2019	12
2020	13
2021	15
2022	8
2023	9
2024	4

1

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Jin J, Wu Y, Chen J, Shen Y, Zhang L, Zhang H, Chen L, Yuan H, Chen H, Zhang W, Luan X. Jin J, et al. Among authors: shen y. Theranostics. 2020 Aug 8;10(22):10141-10153. doi: 10.7150/thno.46985. eCollection 2020. Theranostics. 2020. PMID: 32929339 Free PMC article. Review.

2

Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.

Shen YW, Zhou YD, Chen HZ, Luan X, Zhang WD. Shen YW, et al. Trends Cancer. 2021 Jun;7(6):511-524. doi: 10.1016/j.trecan.2020.12.001. Epub 2020 Dec 25. Trends Cancer. 2021. PMID: 33358571 Review.

3

CD47: Beyond an immune checkpoint in cancer treatment.

Bian HT, Shen YW, Zhou YD, Nagle DG, Guan YY, Zhang WD, Luan X. Bian HT, et al. Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188771. doi: 10.1016/j.bbcan.2022.188771. Epub 2022 Aug 2. Biochim Biophys Acta Rev Cancer. 2022. PMID: 35931392 Review.

4

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.

Lin J, Jin J, Shen Y, Zhang L, Gong G, Bian H, Chen H, Nagle DG, Wu Y, Zhang W, Luan X. Lin J, et al. Among authors: shen y. Theranostics. 2021 Jul 13;11(17):8337-8349. doi: 10.7150/thno.62686. eCollection 2021. Theranostics. 2021. PMID: 34373745 Free PMC article. Review.

5

Cytotoxic and antitumor peptides as novel chemotherapeutics.

Luan X, Wu Y, Shen YW, Zhang H, Zhou YD, Chen HZ, Nagle DG, Zhang WD. Luan X, et al. Nat Prod Rep. 2021 Jan 1;38(1):7-17. doi: 10.1039/d0np00019a. Epub 2020 Aug 10. Nat Prod Rep. 2021. PMID: 32776055 Free PMC article. Review.

6

Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.

Huang R, Shen YW, Guan YY, Jiang YX, Wu Y, Rahman K, Zhang LJ, Liu HJ, Luan X. Huang R, et al. Acta Biomater. 2020 Oct 15;116:1-15. doi: 10.1016/j.actbio.2020.09.009. Epub 2020 Sep 7. Acta Biomater. 2020. PMID: 32911102 Review.

7

The multifaceted involvement of exosomes in tumor progression: Induction and inhibition.

Gu WJ, Shen YW, Zhang LJ, Zhang H, Nagle DG, Luan X, Liu SH. Gu WJ, et al. MedComm (2020). 2021 Jul 1;2(3):297-314. doi: 10.1002/mco2.49. eCollection 2021 Sep. MedComm (2020). 2021. PMID: 34766148 Free PMC article. Review.

8

Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.

Zhang HJ, Zhang XH, Liu J, Sun LN, Shen YW, Zhou C, Zhang HW, Xie LJ, Chen J, Liu Y, Wang YQ. Zhang HJ, et al. Pharmacol Res. 2020 Feb;152:104606. doi: 10.1016/j.phrs.2019.104606. Epub 2019 Dec 14. Pharmacol Res. 2020. PMID: 31846760 Review.

9

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.

Zhang H, Shen YW, Zhang LJ, Chen JJ, Bian HT, Gu WJ, Zhang H, Chen HZ, Zhang WD, Luan X. Zhang H, et al. Front Oncol. 2021 May 24;11:687120. doi: 10.3389/fonc.2021.687120. eCollection 2021. Front Oncol. 2021. PMID: 34109132 Free PMC article. Review.

10

Application of omics- and multi-omics-based techniques for natural product target discovery.

Zhang HW, Lv C, Zhang LJ, Guo X, Shen YW, Nagle DG, Zhou YD, Liu SH, Zhang WD, Luan X. Zhang HW, et al. Biomed Pharmacother. 2021 Sep;141:111833. doi: 10.1016/j.biopha.2021.111833. Epub 2021 Jun 25. Biomed Pharmacother. 2021. PMID: 34175822 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

118 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year